*ILARIS is approved for the treatment of active Still’s disease including Adult-Onset Still’s Disease and Systemic Juvenile Idiopathic Arthritis in patients ≥2 years old. 

Welcome to the virtual booth for ILARIS from Novartis. If you have any questions a Novartis representative will be available during exhibit hours.


ILARIS Full Prescribing Information 

About Novartis

HCP Website 



ILARIS® (canakinumab) is an interleukin-1β blocker indicated for the treatment of the following autoinflammatory Periodic Fever Syndromes: 

    • Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children aged 4 years and older, including: 
      • Familial Cold Autoinflammatory Syndrome (FCAS) 
      • Muckle-Wells Syndrome (MWS) 
    • Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adults and pediatric patients 
    • Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) in adults and pediatric patients 
    • Familial Mediterranean Fever (FMF) in adults and pediatric patients 

ILARIS® (canakinumab) is indicated for the treatment of active Still’s disease, including Adult-Onset Still’s Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older. 



ILARIS is contraindicated in patients with confirmed hypersensitivity to the active substance or to any of the excipients. 


Serious Infections 

ILARIS has been associated with an increased risk of serious infections. Physicians should exercise caution when administering ILARIS to patients with infections, a history of recurring infections or underlying conditions, which may predispose them to infections.  

ILARIS should not be administered to patients during an active infection requiring medical intervention. Administration of ILARIS should be discontinued if a patient develops a serious infection.  

Infections, predominantly of the upper respiratory tract, in some instances serious, have been reported with ILARIS. Generally, the observed infections responded to standard therapy. Isolated cases of unusual or opportunistic infections (egaspergillosis, atypical mycobacterial infections, cytomegalovirus, herpes zoster) were reported during ILARIS treatment. A causal relationship of ILARIS to these events cannot be excluded. In clinical trials, ILARIS has not been administered concomitantly with Tumor Necrosis Factor (TNF) inhibitors. An increased incidence of serious infections has been associated with administration of another interleukin-1 (IL-1) blocker in combination with TNF inhibitors. Coadministration of ILARIS with TNF inhibitors is not recommended because this may increase the risk of serious infections. 

 Drugs that affect the immune system by blocking TNF have been associated with an increased risk of new tuberculosis (TB) and reactivation of latent TB. It is possible that use of IL-1 inhibitors, such as ILARIS, increases the risk of reactivation of TB or of opportunistic infections. 

Prior to initiating immunomodulatory therapies, including ILARIS, patients should be evaluated for active and latent TB infection. Appropriate screening tests should be performed in all patients. ILARIS has not been studied in patients with a positive TB screen, and the safety of ILARIS in individuals with latent TB infection is unknown. Patients testing positive in TB screening should be treated by standard medical practice prior to therapy with ILARIS. All patients should be instructed to seek medical advice if signs, symptoms, or high risk exposure suggestive of TB (eg, persistent cough, weight loss, subfebrile temperature) appear during or after ILARIS therapy. 


 The impact of treatment with anti-IL-1 therapy on the development of malignancies is not known. However, treatment with immunosuppressants, including ILARIS, may result in an increase in the risk of malignancies. 


Hypersensitivity reactions have been reported with ILARIS therapy. During clinical trials, no anaphylactic reactions attributable to treatment with canakinumab have been reported. It should be recognized that symptoms of the underlying disease being treated may be similar to symptoms of hypersensitivity. If a severe hypersensitivity reaction occurs, administration of ILARIS should be discontinued and appropriate therapy initiated. 


Live vaccines should not be given concurrently with ILARIS. Prior to initiation of therapy with ILARIS, patients should receive all recommended vaccinations. In addition, because ILARIS may interfere with normal immune response to new antigens, vaccinations may not be effective in patients receiving ILARIS. 

Canakinumab, like other monoclonal antibodies, is actively transported across the placenta mainly during the third trimester of pregnancy and may cause immunosuppression in the in utero exposed infant. The risks and benefits should be considered prior to administering live vaccines to infants who were exposed to ILARIS in utero for at least 4 to 12 months following the mother’s last dose of ILARIS. 

Macrophage Activation Syndrome 

Macrophage Activation Syndrome (MAS) is a known, life-threatening disorder that may develop in patients with rheumatic conditions, in particular Still’s disease, and should be aggressively treated. Physicians should be attentive to symptoms of infection or worsening of Still’s disease as these are known triggers for MAS. Eleven cases of MAS were observed in 201 SJIA patients treated with canakinumab in clinical trials. Based on the clinical trial experience, ILARIS does not appear to increase the incidence of MAS in Still’s disease patients, but no definitive conclusion can be made. 


Serious adverse reactions reported with ILARIS in the CAPS clinical trials included infections and vertigo. The most common adverse reactions greater than 10% associated with ILARIS treatment in CAPS patients were nasopharyngitis, diarrhea, influenza, rhinitis, headache, nausea, bronchitis, gastroenteritis, pharyngitis, weight increased, musculoskeletal pain, and vertigo. 

The most common adverse reactions greater than or equal to 10% reported by patients with TRAPS, HIDS/MKD, and FMF treated with ILARIS were injection site reactions and nasopharyngitis. 

The most common adverse drug reactions greater than 10% associated with ILARIS treatment in SJIA patients were infections (nasopharyngitis and upper respiratory tract infections), abdominal pain, and injection site reactions. 

Please see full Prescribing Information, including Medication Guide, for ILARIS in link provided above. 


11/20 ILA-1397459


Adrian Hawkins




Laurie Thompson




Mary Beth Mundt




Jim Meakim



RNS Live Virtual Events

Session Description

An Interdisciplinary Approach to Rheumatic Diseases

In this panel presentation, you will hear from multiple specialities regarding the best practices on treating rheumatic diseases.

Session Description

Differentiating Between Ehlers-Danlos Syndrome and Other Hypermobility Syndromes

Take an assiduous look at the complexities between Ehlers-Danlos syndromes (EDS) and other hypermobility syndrome (HMS) as we discuss clinical manifestations, the diagnostic workup, and what long term outcomes are for the hypermobility syndrome and Ehlers-Danlos syndromes patient.

Session Description

Pregnancy and Women’s Health in Psoriatic Arthritis (PsA)

In this session you will learn about how Psoriatic Arthritis (PsA) impacts your pregnant patients and the latest American College of Rheumatology guidelines.

Session Description

Treating Interstitial Lung Disease (ILD) in Sarcoidosis

Interstitial lung disease (ILD), sarcoidosis is lesser known in the specialty of rheumatology and requires a multidisciplinary approach to treatment. This session will provide the pathophysiology and disease process in interstitial lung disease, as well as treatment and support considerations in interstitial lung disease patients with sarcoidosis.

Session Description

An Integrative and Alternative Approach to Rheumatology Patient Care

In this session, we will take a look at an integrative approach to patient care, combining complementary and alternative treatments in addition to medical therapies commonly applied in rheumatology.

Session Description

An Overview of Vasculitis for the Nurse and Advanced Practice Provider

Vasculitis can range from mild to life threatening symptoms, so it is important as providers to know where your patient falls on the spectrum. This session will cover a global overarching review of the disease, including detection, manifestations, and treatments.

Session Description

What Antiphospholipid Syndrome (APS) Looks Like in the Rheumatology Patient

In this session, we will be walking through diagnosis to care for our patients with antiphospholipid syndrome (APS). We will be discussing pathophysiology, immunology, differential diagnosis, clinical presentation, and treatment of antiphospholipid syndrome.

Session Description

A Deeper Dive into Spondylitis with You and Your Patient

Though patients may not pay attention to codes that their healthcare providers jot down, nurses and advanced practice providers know just how important that clerical detail can be. In this session, we will break down what the recent ICD-10 classification of non-radiographic axial spondyloarthritis (nr-axSpA) means for you as a provider and the future treatment of non-radiographic axial spondyloarthritis.

Session Description

Updates on Guidelines in Treating Your Gout Patients

Gout is the most common form of inflammatory arthritis seen in rheumatology patients, and the American College of Rheumatology (ACR) released in 2020 new Guidelines for the Management of Gout. In this learning session we will be exploring the these updated treatment guidelines as well as recent and pipeline treatments so we can best serve our patients with the most current research released.

Session Description

Where Are We Now? A Look Back Through COVID-19 as of Fall 2020

It’s been nearly one year since COVID-19 was first identified as an infectious disease. Through the evolution and spread of the disease, we have learned a lot about what works and what we should avoid. In this session, we will talk about the most recent updates to treatment options for patients, particularly those with rheumatic diseases.

Session Description

How Genetics Will Impact the Future of Rheumatology

In this session, we will introduce translational genetics and genomics through the lenses of rheumatic diseases, such as Behcet’s Disease, Stills Disease, and Systemic Onset Juvenial Idiopathic Arthritis (SoJIA).

Session Description

Pregnancy and Women's Health in Rheumatoid Arthritis (RA)

Rheumatoid arthritis (RA) presents differently throughout a woman’s journey into motherhood. From disease activity improvements to flare ups, learn what rheumatoid arthritis looks like from conception to post-partum, and how best to support mothers throughout the process.

Session Description

Transitioning your Lupus Patient from Pediatric to Adult Care

Transfer of care from pediatrics to adults can be difficult for patients, especially for patients diagnosed with lupus, a disease with a high rate of comorbidity. In this session, we will address comorbid manifestations in lupus, and how to best prepare our patients for their transition to adult providers.

Session Description

Immunology in Rheumatoid Arthritis

In this session, we will discuss the application of the fundamentals of immunology in patients with rheumatoid arthritis.

Session Description

Of Mice and Men: DMOAD Therapy for the Osteoarthritic Knee

This session will focus on the common findings, challenges, and targets of therapy including the use of disease modifying osteoarthrits drugs (DMOADS) in patients with osteoarthritic knees.


Our individual sessions are not yet available for registration

We will be getting this registration up and running in the next couple of days.

Please check back soon!

Session Description

An Overview of Interstitial Lung Disease (ILD), Ehler's Danlos Syndrome (EDS), and Polymyalgia Rheumatica (PMR)

A rapid fire approach to understanding Interstitial Lung Disease (ILD), Ehler’s Danlos Syndrome (EDS), and Polymyalgia Rheumatica (PMR).

Session Description

Latest Treatments and Guidelines in Vasculitis and Giant Cell Arteritis (GCA)

In this session, we will cover giant cell arteritis (GCA) as the most common form of vasculitis.

Session Description

The Role and Impact of Infusible Therapies on Your Practice

In this session, learners will develop an understanding of the role and impact of infusion therapies and it’s impact in clinical rheumatology practice.

Session Description

The Progression of Lupus and Research

In this session, we will explore the history and progression of lupus and research in systemic lupus erythematosus (SLE) and lupus nephritis (LN).